Wall Street Zen Downgrades LeMaitre Vascular to Hold Rating

LeMaitre Vascular (NASDAQ:LMAT) has faced a downgrade from Wall Street Zen, shifting its rating from “buy” to “hold” in a report released on November 7, 2023. This change reflects a broader reassessment of the company by various financial analysts, who have issued mixed evaluations of the stock’s future performance.

Several other research firms have also adjusted their positions regarding LeMaitre Vascular. On the same day as Wall Street Zen’s downgrade, Wells Fargo & Company reduced its price target for the company from $97.00 to $93.00 while maintaining an “equal weight” rating. Cantor Fitzgerald reiterated a “neutral” rating with a price target of $95.00. In contrast, Roth Capital reaffirmed a “buy” rating, setting a price objective at $108.00, and Barrington Research maintained an “outperform” rating with a target of $95.00. Zacks Research offered a more optimistic view, raising its rating from “hold” to “strong-buy” on the same day as the downgrade by Wall Street Zen.

The overall sentiment among analysts is cautiously optimistic, with one analyst issuing a “strong buy” rating, three analysts giving a “buy” rating, and four assigning a “hold” rating. According to MarketBeat, LeMaitre Vascular currently holds an average rating of “Moderate Buy” with a consensus target price of $100.20.

Recent Earnings Performance

LeMaitre Vascular recently announced its earnings results for the third quarter on November 6, 2023. The medical instruments supplier reported earnings per share (EPS) of $0.62, surpassing the analysts’ consensus estimate of $0.57 by $0.05. The company generated revenues of $61.05 million, slightly below the expected $62.18 million.

The firm demonstrated strong performance compared to the previous year, with an 11.4% increase in revenue. In the same quarter last year, LeMaitre Vascular reported an EPS of $0.49. The company has also provided its guidance for fiscal year 2025, projecting EPS between $2.480 and $2.530, with Q4 guidance set at $0.640 to $0.690 EPS. Analysts predict that LeMaitre Vascular will achieve $1.94 EPS for the current year.

Institutional Investor Activity

In recent months, large institutional investors have actively traded shares of LeMaitre Vascular, indicating a growing interest in the company. Cetera Investment Advisers increased its stake by 209.6% during the first quarter, now holding 8,522 shares valued at approximately $715,000. US Bancorp DE also raised its holdings by 36.0%, acquiring an additional 368 shares, bringing its total to 1,390 shares valued at $117,000.

Cynosure Group LLC boosted its stake by 13.5%, now owning 3,709 shares worth $311,000. Invesco Ltd. expanded its position by 34.5%, owning 235,436 shares valued at $19.75 million. Additionally, Nuveen LLC purchased a new stake worth $4.631 million during the first quarter. Currently, approximately 84.64% of LeMaitre Vascular’s stock is held by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc. specializes in developing, manufacturing, and marketing medical devices and implants for vascular surgery on a global scale. Their product offerings include human cadaver tissue cryopreservation services, angioscopes, embolectomy and thrombectomy catheters, occlusion catheters, and perfusion catheters.

As the company navigates through these recent changes in ratings and stock performance, analysts and investors will be closely monitoring its upcoming developments and market strategies.